Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Change in Receivables (2020 - 2025)

Bioventus (BVS) has disclosed Change in Receivables for 6 consecutive years, with -$1.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables fell 132.54% year-over-year to -$1.9 million, compared with a TTM value of $916000.0 through Dec 2025, down 91.41%, and an annual FY2025 reading of $916000.0, down 91.41% over the prior year.
  • Change in Receivables was -$1.9 million for Q4 2025 at Bioventus, down from -$1.8 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $25.6 million in Q3 2022 and bottomed at -$17.1 million in Q3 2024.
  • Average Change in Receivables over 5 years is $2.0 million, with a median of $1.9 million recorded in 2023.
  • The sharpest move saw Change in Receivables skyrocketed 989.74% in 2024, then tumbled 559.86% in 2025.
  • Year by year, Change in Receivables stood at $6.9 million in 2021, then crashed by 30.0% to $4.8 million in 2022, then surged by 90.23% to $9.2 million in 2023, then crashed by 36.99% to $5.8 million in 2024, then crashed by 132.54% to -$1.9 million in 2025.
  • Business Quant data shows Change in Receivables for BVS at -$1.9 million in Q4 2025, -$1.8 million in Q3 2025, and $13.6 million in Q2 2025.